Reviva Pharmaceuticals Email Format
Biotechnology ResearchCalifornia, United States11-50 Employees
Reviva Pharmaceuticals is a late-stage biotechnology company focused on developing therapies for central nervous system, inflammatory, and cardiometabolic diseases. Its lead candidate, RP5063, is described as a multimodal neuromodulator that has completed global Phase 2 trials and is proceeding toward Phase 3 for schizophrenia, with potential expansion into related neuropsychiatric conditions. The firm emphasizes a development approach aimed at speed without compromising quality, leveraging a strong patent portfolio and an internal discovery pipeline to address unmet medical needs. Based in the San Francisco Bay Area, Reviva operates in the biotechnology research sector and is led by an experienced management team with a background in advancing drugs through development toward global markets. The company engages with the broader neuroscience and inflammatory disease communities through industry events and conferences, highlighting ongoing clinical work and potential future indications for RP5063 in disorders such as bipolar disorder, major depressive disorder, and other neuropsychiatric conditions.